ADCT · Categories · Downgrades
ADCT - Analyst downgrades
ADC Therapeutics SA (ADCT) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for ADCT
- ADC Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded ADC Therapeutics from Buy to Neutral
- ADC Therapeutics downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ADC Therapeutics from Outperform to Sector Perform and set a new price target of $2.00
- ADC Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded ADC Therapeutics from Neutral to Underperform and set a new price target of $2.00 from $7.00 previously
- ADC Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded ADC Therapeutics from Buy to Neutral and set a new price target of $7.00 from $14.00 previously
- ADC Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded ADC Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $17.00 previously
Other ADCT categories
Is something on this page wrong? Request a change